Childhood B-Lymphoblastic Leukemia Treatment Study

AALL 1331 is a group wide risk-stratified, randomized phase III study to test whether incorporation of blinatumomab into the treatment of patients with childhood B-lymphoblastic leukemia (B-ALL) at first relapse will improve disease free survival. Blinatumomab is being tested in this population based on its demonstrated safety profile and single agent activity (induction of MRD-negative remissions in children with multiple relapsed refractory B-ALL).

In order to participate you must meet the following criteria:

• Are between one year of age and 31 years of age at the time of relapse.
• Have had first relapse of B-ALL. Allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular.

This is a partial list of eligibility requirements.